Shares of Amedica Co. (NASDAQ:AMDA) reached a new 52-week low during mid-day trading on Friday . The stock traded as low as $2.33 and last traded at $2.60, with a volume of 32300 shares. The stock had previously closed at $2.60.
Several research firms have issued reports on AMDA. Maxim Group restated a “hold” rating on shares of Amedica in a report on Wednesday, January 24th. ValuEngine upgraded Amedica from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Finally, Ladenburg Thalmann Financial Services downgraded Amedica from a “buy” rating to a “neutral” rating in a report on Monday, November 27th.
Amedica (NASDAQ:AMDA) last posted its quarterly earnings data on Tuesday, November 21st. The medical equipment provider reported ($0.93) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.94) by $0.01. The firm had revenue of $2.96 million for the quarter. Amedica had a negative return on equity of 73.86% and a negative net margin of 71.07%. research analysts predict that Amedica Co. will post -6.12 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Amedica (AMDA) Sets New 1-Year Low at $2.33” was published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://stocknewstimes.com/2018/02/18/amedica-amda-sets-new-1-year-low-at-2-33.html.
Amedica Corporation is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty.
Receive News & Ratings for Amedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedica and related companies with MarketBeat.com's FREE daily email newsletter.